Welcome to LookChem.com Sign In|Join Free
  • or
Chemtn Biological Technology LimitedAprepitant C23H21F7N4O3//file1.lookchem.com/cas/reactions/2021/06/03/8096869.png

Communicate with Supplier:

Mr. Kerry
Mr. Kerry: What can I do for you?

Aprepitant C23H21F7N4O3 CAS NO.170729-80-3

Min.Order Quantity:
10 Gram
Purity:
99%
Port:
Tianjin xingang
Payment Terms:
T/T,MoneyGram,Other

Add to Inquiry Cart

Product Details

Keywords

  • Aprepitant
  • 170729-80-3,chemical
  • research,C23H21F7N4O3

Quick Details

  • ProName: Aprepitant C23H21F7N4O3
  • CasNo: 170729-80-3
  • Molecular Formula: C23H21F7N4O3
  • Appearance: Solid
  • Application: Orally active estrogenic steroid. It w...
  • DeliveryTime: 3days
  • PackAge: in foil bag or customized
  • Port: Tianjin xingang
  • ProductionCapacity: 10 Kilogram/Week
  • Purity: 99%
  • Storage: Refrigerator
  • Transportation: shipping by courier or by sea
  • LimitNum: 10 Gram

Superiority

product name: aprepitant
synonyms: 5-[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)morpholin-4-ylmethyl]-3,4-dihydro-2h-1,2,4-triazol-3-one;aprepitant;5-[[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,;5-[[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one, emend;5-[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)morpholin-4-ylmethyl]-3,4-dihydro-2h-1,2,4-triazol-3-one;5-[[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one;emend;mk-0869
cas: 170729-80-3
mf: c23h21f7n4o3
mw: 534.4266624

Details

aprepitant usage and synthesis
anti-vomiting drug during chemotherapy aprepitant is a neurokinin-1 (nk-1) receptor antagonist and belongs to the treating agents of vomiting during chemotherapy of cancer. it was first successfully developed by merck company (german). in march 2003, the us food and drug administration approved it for being used in the treatment of chemotherapy vomiting. this product has a high selective affinity to human beings while has a low affinity to serotonin, dopamine and glucocorticoid receptor affinity. aprepitant, when combined with 5-ht3 receptor inhibitors (such as ondansetron hydrochloride) and the corticosteroid dexamethasone, can further alleviate the cisplatin-induced acute and (or) delayed emesis. applying this drug alone can have some preventive effect.
substance p, a kind of tachykinin (neurokinin), is mainly distributed in the neurons of central and peripheral nervous system. it is related with a lot of features such as vomiting, depression, inflammatory pain and other inflammatory diseases. the role of substance p is mediated by nk-1 receptor which is a kind of g protein receptor coupled with phosphoinositide signaling pathway. the drug has blocking effect on the nk-1 receptor through direct binding to this receptor, thus further obtaining the treatment of substance p-mediated diseases.
aprepitant can selectively prevent the binding of substance p with nk-1 receptor in the central nervous system to take antiemetic effect. therefore, it can be used for treating the nausea and vomiting caused by the moderately and highly emetogenic chemotherapy.
dose and usage when being used for treating the chemotherapy-induced nausea and vomiting, aprepitant is often used in combination with ondansetron (only at the first day of administration) and dexamethasone. detailed as follows:
at 30 min before chemotherapy, intravenously inject 32 mg of ondansetron, taking 12 mg of dexamethasone; at the morning of 2 ~ 4d, take 8 mg of dexamethasone again.
for nausea and vomiting induced by chemotherapy, use a initial dose of 125mg at the first day, administer at 1 hour before chemotherapy; the first 2 ~ 3d, daily 80mg; administer at 1 h before chemotherapy; for treating severe depression (with anxiety) administer 300mg each time, qd. however, the efficacy is still not clear. the above instruction doesn’t need dose adjustment for different gender or races. for patients of renal insufficiency, there is no need for dose adjustment; for mild to moderate liver dysfunction, there is no need to adjust the dose as well; we are currently still lack of pharmacokinetic data when severe liver damage happens. it is also not necessary for the elderly to adjust the dose. there is also no need for dose adjustment to patients who are undergoing hemodialysis due to advanced renal disease.
the above information is edited by the chemicalbook of dai xiongfeng.
adverse reactions gastrointestinal reaction: when used for the prevention of chemotherapy-induced emesis, aprepitant may cause diarrhea, but clear relationship is still lacking.
central nervous system: the drug can cause drowsiness and weakness (or lack thereof), but statistical significance was not obvious.
genitourinary system: when aprepitant is applied for the treatment of severe depression, sexual dysfunction can occur.
respiratory system: the drug is used for the prevention of chemotherapy-induced emesis, can also cause hiccups. but the clinical significance is not clear.
skin: occasionally history - johnson syndrome, urticaria and angioedema can occur.
liver: when aprepitant is used for the prevention of chemotherapy-induced emesis, it can cause the increase of serum aminotransferase, but the clinical significance is unclear. no cases of liver toxicity had been reported.
application antineoplastic drug.
chemical properties off-white to light yellow cyrstalline solid
usage a novel selective neurokinin-1 (nk-1) receptor antagonist. in vitro studies using human liver microsomes indicate that aprepitant is metabolised primarily by cyp3a4 with minor metabolism by cyp1a2 and cyp2c19, and no metabolism by cyp2d6, cyp2c9, or cyp2e1. antiemetic.
usage anticholinergic

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

Related Products

Related Keywords

Inquiry Cart 0